Friday, July 31, 2026

BabyMonster Thanks Fans as ‘Forever’ Dance Video Goes Behind the Scenes

YG Entertainment has unveiled the behind-the-scenes dance video for BabyMonster's latest song, "Forever."

Truxima: How the First Korean Biosimilar Achieved 35.8% Market Share in the U.S.!

Celltrion’s Truxima becomes South Korea's first biosimilar to lead U.S. prescription market, boosted by tariff exemptions and strong growth.

“North Korea: China’s Newest Province?” Kim’s Desperate Vow of Loyalty Signals a Puppet State Future

Kim Jong Un publicly supports the One China principle, marking a significant moment in North Korea-China relations, according to state media.

Tag: drug

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

HyDIFFUZE™: The Game-Changer in Subcutaneous ADC Delivery for Cancer Treatment

Huons Lab patents a platform technology for ADC subcutaneous injections, enhancing stability and drug delivery efficiency in biopharmaceuticals.

South Korea Eases Phase 3 Trial Requirements for Biosimilars Following U.S. and EU… Early Data Becomes Key Battleground

South Korea's MFDS eases Phase 3 trial requirements for biosimilars, aligning with global trends, enhancing early comparability importance.

HLB’s Rivoceranib Drug Approval: What the FDA’s VAI Classification Means for Liver Cancer Treatment

HLB's Rivoceranib facility received a VAI classification from the FDA, indicating compliance with GMP standards, aiding drug approval progress.

HLB’s Liver Cancer Drug: FDA’s VAI Conclusion Sparks Hope for Approval

HLB's Rivoceranib facility passed FDA inspection, receiving VAI classification, moving towards new liver cancer drug approval.

Inventage Lab to present mRNA-LNP large-scale manufacturing platform at CRS 2026

Inventage Lab showcases its IVL-GeneFluidic® platform for mRNA lipid nanoparticles at CRS 2026, enhancing local manufacturing capabilities.

Global Standards for Stimulant Drug Dependence: What You Need to Know

The world's first international standards for evaluating dependence on stimulant drugs are set to be established by the Ministry of Food and Drug Safety.

2026’s Game-Changer: Inventage Lab’s BioFluidic Technology Revolutionizes Antibody Drug Administration

Inventage Lab's CEO emphasizes the importance of platform technology for drug delivery systems and open innovation in the pharmaceutical industry.

SK Chemicals and J2H Biotech Partner for Breakthrough MASH Treatment: What You Need to Know

SK Chemicals partners with J2H Biotech to develop J2H-1702, a treatment for metabolic-associated steatotic liver disease, enhancing drug pipeline.

Dong-A ST Eyes Early-Stage Licensing Deals as Key Growth Strategy, Says VP Oh Yoon-seok [BIO USA]

Dong-A ST aims for global expansion by licensing preclinical drug candidates, focusing on timely execution of R&D strategies by 2027.

Mexico Recognizes South Korea’s MFDS: What This Means for Drug Approvals

Mexico recognizes South Korea's MFDS as a reference authority, streamlining drug approvals and enhancing market access for Korean firms.

Hyundai Bioscience’s Xafty Clears Genotoxicity Study, Supporting U.S. Phase 2 Respiratory Virus Trial Plans

Hyundai Bioscience's Xafty shows no genotoxicity in tests, aiding its Phase 2 trial plans for respiratory viral infections.

Moxidectin vs. Traditional Heartworm Preventatives: Which Offers Better Protection in 2026?

Reports of drug resistance in heartworm prevention highlight the need for moxidectin-based strategies to combat ML-resistant strains.

Revolutionary Drug Delivery: How Nasal Nanoparticles Target Glioblastoma with Magnetic Precision

Korean researchers developed a nasal drug delivery method using magnetic fields to target glioblastomas, significantly improving survival rates.

IVL3021 vs Wegovy: The Future of Long-Acting Obesity Treatments Revealed

Inventage Lab's IVL3021 shows promising long-term obesity treatment results, outperforming competitors with effective weight maintenance strategies.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.